CHEK2 truncating mutations (OR = 1.62, 95% CI 1.03–2.51, p = 0.041) (Table 3) and CHEK2, p.1100delC alone (OR = 1.85, 95% CI 1.13–3, p = 0.017) were also enriched in FBC.23, 24 The personal history of bilateral breast cancer and other cancers were not statistically significantly higher for ATM or CHEK2 mutation carriers compared to mutation-negative women (Table 4). This evidence concerns the gene CHEK2 and cancer.